In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker ...

A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

A major scientific breakthrough has identified the Epstein-Barr virus (EBV) as the leading cause of multiple sclerosis (MS), ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...